Approved Drug May Be Repurposed to Treat Tumors Resulting from NF2-Related Schwannomatosis
Mass General-led phase 2 clinical trial generates promising results for brigatinib as a treatment for the genetic condition, which is characterized by brain and nerve sheath tumors.